A multicenter prospective evaluation of the benefits of Dexcom ONE plus in subjects with type 2 diabetes on insulin therapy beyond glycemic control: results from the LIFE-ONE study


Por: Chico, A, Aguilera-Hurtado, E, Albareda, M, Moreno-Fernández, J, Beato-Vibora, P, Fernández-Rubio, E, Cuesta, M, Bartual, A, Ampudia-Blasco, FJ, Bandrés, O, Ares, J, Rivero, MT and Picón-César, MJ

Publicada: 11 abr 2026 Ahead of Print: 1 abr 2026
Resumen:
Aims Continuous glucose monitoring (CGM) has demonstrated to improve glucose control in people with type 2 diabetes (T2D) especially in those on insulin therapy. Dexcom ONE + is a CGM system with some particular features, however, there is no clinical study conducted with this device. The aim was to determine whether Dexcom ONE + can improve glucose control and patient-reported outcomes in insulin-treated T2D subjects. Methods Prospective, multicenter study including T2D on multiple insulin injections (MDI) or basal insulin (BI), with-out CGM experience and HbA1c > 7% (53 mmol/l). They used blinded Dexcom ONE + for 10 days and in open mode for 12 weeks. HbA1c, CGM-metrics, quality of life, fear and awareness of hypoglycemia were obtained baseline and at 12-weeks, and treatment satisfaction at 12 weeks. Results 159 subjects completed the study (MDI 75, BI 84). HbA1c decreased in MDI group from 8.18 +/- 1.3% (65.9 +/- 3.3 mmol/mol) to 7.34 +/- 0.8% (56.7 +/- 2.1 mmol/mol) and in BI group from 8.13 +/- 1.3% (65 +/- 3.3 mmol/mol) to 7.32 +/- 0.7% (56.5 +/- 1.9 mmol/mol) (p < 0.01). TIR increased in MDI group from 52.1 +/- 25% to 60.7 +/- 22% (p = 0.011) and in BI group from 58.8 +/- 22% to 65.8 +/- 19% (p = 0.0015). High degree of satisfaction and improvement in quality of life were observed in both groups and lower fear of hypoglycemia in BI group. Conclusions In this first clinical study, Dexcom ONE + enhanced glycemic control and improve patient-reported outcomes with high satisfaction.

Filiaciones:
Chico, A:
 Hosp Santa Creu & St Pau Barcelona, Endocrinol & Nutr Dept, C San Quintin 167, Barcelona 08025, Spain

 Inst Recerca St Pau IR St PAU, Barcelona, Spain

 Univ Autonoma Barcelona, Barcelona, Spain

 Inst Salud Carlos III, CIBER BBN, Madrid, Spain

:
 Germans Trias & Pujol Univ Hosp, Endocrinol & Nutr Dept, Badalona, Spain

Albareda, M:
 Complex Hosp Univ Moises Broggi, Endocrinol & Nutr Dept, Barcelona, Spain

Moreno-Fernández, J:
 Ciudad Real Gen Univ Hosp, Endocrinol & Nutr Dept, Ciudad Real, Spain

 Castilla La Mancha Univ, Ciudad Real, Spain

 Castilla La Mancha Inst Hlth Res, Toledo, Spain

Beato-Vibora, P:
 Badajoz Univ Hosp, Endocrinol & Nutr Dept, Badajoz, Spain

Fernández-Rubio, E:
 Cruces Univ Hosp, Endocrinol & Nutr Dept, Bilbao, Spain

Cuesta, M:
 Hosp Clin Univ San Carlos, Endocrinol & Nutr Dept, Madrid, Spain

 Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Madrid, Spain

 Univ Complutense Madrid, Madrid, Spain

 Inst Salud Carlos III, CIBERDEM, Madrid, Spain

Bartual, A:
 Clin Univ Hosp Valencia, Endocrinol & Nutr Dept, Valencia, Spain

Ampudia-Blasco, FJ:
 Clin Univ Hosp Valencia, Endocrinol & Nutr Dept, Valencia, Spain

 Univ Valencia, Valencia, Spain

Bandrés, O:
 Lozano Blesa Univ Hosp, Endocrinol & Nutr Dept, Zaragoza, Spain

Ares, J:
 Cent Univ Hosp Asturias, Endocrinol & Nutr Dept, Oviedo, Spain

 Inst Invest Sanitaria Principado Asturias, Oviedo, Spain

 Univ Oviedo, Oviedo, Spain

Rivero, MT:
 Complejo Hosp Univ Ourense, Endocrinol & Nutr Dept, Ourense, Spain

Picón-César, MJ:
 Virgen La Victoria Univ Hosp, Endocrinol & Nutr Dept, Malaga, Spain

 Inst Invest Biomed Malaga, Malaga, Spain

 Plataforma Nanomed IBIMA Plataforma BIONAND, Malaga, Spain

 Inst Salud Carlos III, CIBERObn, Madrid, Spain
ISSN: 09405429





Acta Diabetologica
Editorial
Springer-Verlag Italia s.r.l., VIA DECEMBRIO, 28, MILAN, 20137, ITALY, Alemania
Tipo de documento: Article
Volumen: 63 Número: 6
Páginas: 1057-1066
WOS Id: 001737991900001
ID de PubMed: 41964691
imagen Green Submitted

MÉTRICAS